Masimo Co. (NASDAQ:MASI) Stock Holdings Cut by Intrust Bank NA

Intrust Bank NA reduced its position in Masimo Co. (NASDAQ:MASI) by 5.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,493 shares of the medical equipment provider’s stock after selling 188 shares during the quarter. Intrust Bank NA’s holdings in Masimo were worth $483,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. MML Investors Services LLC raised its position in Masimo by 1.4% in the 4th quarter. MML Investors Services LLC now owns 6,401 shares of the medical equipment provider’s stock valued at $687,000 after purchasing an additional 86 shares in the last quarter. Securian Asset Management Inc raised its position in shares of Masimo by 1.7% during the 4th quarter. Securian Asset Management Inc now owns 5,955 shares of the medical equipment provider’s stock worth $639,000 after acquiring an additional 100 shares in the last quarter. Utah Retirement Systems raised its position in shares of Masimo by 1.2% during the 4th quarter. Utah Retirement Systems now owns 8,500 shares of the medical equipment provider’s stock worth $913,000 after acquiring an additional 100 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Masimo by 2.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 4,413 shares of the medical equipment provider’s stock worth $473,000 after acquiring an additional 113 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Masimo by 0.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 23,693 shares of the medical equipment provider’s stock worth $3,276,000 after acquiring an additional 116 shares in the last quarter. Institutional investors own 83.03% of the company’s stock.

In other Masimo news, EVP Yongsam Lee sold 9,035 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $146.60, for a total transaction of $1,324,531.00. Following the completion of the sale, the executive vice president now owns 75,728 shares of the company’s stock, valued at $11,101,724.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Anand Sampath sold 30,000 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $142.39, for a total value of $4,271,700.00. Following the completion of the sale, the executive vice president now directly owns 27,518 shares of the company’s stock, valued at approximately $3,918,288.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 99,829 shares of company stock valued at $14,096,943. 11.50% of the stock is owned by company insiders.

Shares of NASDAQ MASI traded down $2.60 during trading on Wednesday, reaching $141.80. The company had a trading volume of 184,601 shares, compared to its average volume of 442,246. The stock has a market capitalization of $7.63 billion, a PE ratio of 46.80, a PEG ratio of 2.89 and a beta of 1.09. The business’s 50-day simple moving average is $139.90. Masimo Co. has a twelve month low of $96.14 and a twelve month high of $148.63.

Masimo (NASDAQ:MASI) last released its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The firm had revenue of $231.70 million during the quarter, compared to analyst estimates of $223.67 million. During the same period in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. Sell-side analysts anticipate that Masimo Co. will post 3.12 earnings per share for the current fiscal year.

Several research firms have commented on MASI. Piper Jaffray Companies lifted their price target on Masimo from $148.00 to $160.00 in a research report on Friday, May 17th. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $153.00 price target on the stock in a research report on Wednesday, May 8th. Needham & Company LLC reiterated a “buy” rating on shares of Masimo in a research note on Tuesday, April 9th. BidaskClub downgraded Masimo from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 19th. Finally, UBS Group lifted their price target on Masimo from $147.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Masimo currently has an average rating of “Buy” and a consensus target price of $154.25.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: How to Use a Moving Average for Trading 

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply